Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
The lab will facilitate the development of herbal and natural-based solutions
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Subscribe To Our Newsletter & Stay Updated